Clinical Efficacy And Adverse Reactions Of Different Chemotherapy Regimens In The Treatment Of Recurrent Serous Ovarian Cancer

Objective:This article discusses the clinical efficacy and adverse reactions of patients with recurrent serous ovarian cancer after choosing different chemotherapy regimens,hoping to provide basis for patients with recurrent serous ovarian cancer to choose individualized chemotherapy regimens,improve the quality of life of patients and prolong the survival period of patients.Methods: The clinical data of 196 patients with recurrent serous ovarian carcinoma admitted to Hunan Cancer Hospital from 2012 to 2015 were retrospectively analyzed.The collected patients were divided into platinum-sensitive group(130 cases)and platinum-resistant group(66cases)according to the time of recurrence(>6months or ?6 months).Platinum-sensitive patients were divided into two groups: docetaxel platinum(group A)and paclitaxel cisplatin(group B).Platinum-resistant patients were divided into three groups:gemcitabine oxaliplatin(group C),doxorubicin liposome(group D)and etoposide(group E).We comparedthe variation of CA125 before and after 4 courses of chemotherapies between group A and B.The clinical efficacy,incidence of adverse reactions and survival rate after relapse after treatment with different chemotherapy regimens were compared according to the patients' choices of different chemotherapy regimens.The short-term clinical efficacy of patients was evaluated according to the Response Evaluation Criteria In Solid Tumors,and the adverse reactions of patients were evaluated according to the classification criteria for common adverse reactions of anticancer drugs formulated by WHO.SPSS17.0 statistical software was used for statistical analysis.N(%)was used for statistical description of enumeration data and the comparison between groups was performed by chi-square test or Fisher exact test.The measurement data was expressed by(x ± s),and the intragroup difference of measurement data was compared with the t test.P<0.05 is statistically significant.Results: 1.There was no significant difference in serum CA125 level between group A and group B before and after 3 courses of chemotherapy(P>0.05).2.There was no significant difference in the overall response rate and clinical benefit rate between group A and group B(P>0.05).3.There was no significant difference in the incidence of grade?,?and ? myelosuppression and liver injury between group A and group B(P>0.05).The incidence of grade ? myelosuppression in group Awas higher than that in group B,and the difference was statistically significant(P=0.018,P<0.05).Renal injury in group B was significantly higher than that in group A,the difference was statistically significant(P=0.011,P<0.05).4.There was no significant difference in 3-year survival rate between group A and group B(P=0.431,P>0.05).5.There was no significant difference in the overall response rate of chemotherapy among the three groups of C,D and E(P=0.378,P>0.05).6.There was no significant difference in the incidence of myelosuppression(grade I-III)and damage of liver and renal fuction among the three groups of C,D and E(P>0.05).The incidence of myelosuppression(grade ?)was higher in group C,and the comparison among the three groups was statistically significant(P=0.022,P<0.05).7.There was a significant difference in 1-year survival rate among the group of C,D and E after the recurrence of platinum resistance(P<0.05).Conclusion:1.The efficacy of cisplatin or carboplatin combines with paclitaxel in the treatment of the patients with platinum-sensitive relapse is similar,but the toxicity is different;the incidence of myelosuppression in patients treated with carboplatin is higher than that of cisplatin,while the incidence of renal injury caused by cisplatin is higher than that of carboplatin.2.The effective rate of gemcitabine+oxaliplatin,PLD and etoposide was about 11-30%,and etoposide is relatively less effective.Myelosuppression is more severe in the group of gemcitabine+oxaliplatin.